ArticlePloS one2016
Renal Transplant Recipients Treated with Calcineurin-Inhibitors Lack Circulating Immature Transitional CD19+CD24hiCD38hi Regulatory B-Lymphocytes.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 49 citations in OpenAlex.
- B-cell dynamics during experimental endotoxemia in humans.Bioscience reports · 2019Trial
- Early Post-Transplant Peripheral B-Cell Profiles in Kidney Transplant Recipients: Clinical Associations and Limitations.Journal of clinical medicine · 2026Article
- CD40 blockade hampers IgG class-switch while enhancing Granzyme B production by transitional B cells.Clinical and experimental immunology · 2025Article
- Review
- Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation.Frontiers in immunology · 2023Article
- Encephalitis Caused by Jamestown Canyon Virus in a Liver Transplant Patient, North Carolina, USA, 2017.Open forum infectious diseases · 2022Article
- Biomarkers of immune tolerance in kidney transplantation: an overview.Pediatric nephrology (Berlin, Germany) · 2022Review
- Relationship of transitional regulatory B and regulatory T cells and immunosuppressive drug doses in stable renal transplant recipients.Immunity, inflammation and disease · 2021Article
- Monitoring of B Cell in Kidney Transplantation: Development of a Novel Clusters Analysis and Role of Transitional B Cells in Transplant Outcome.Diagnostics (Basel, Switzerland) · 2021Article
- Regulatory B Cell Therapy in Kidney Transplantation.Frontiers in pharmacology · 2021Review
- Regulatory B cells: TIM-1, transplant tolerance, and rejection.Immunological reviews · 2021Review
- Approaches for Controlling Antibody-Mediated Allograft Rejection Through Targeting B Cells.Frontiers in immunology · 2021Review
- Deficit of circulating CD19British journal of haematology · 2020Article
- Mechanisms of organ transplant injury mediated by B cells and antibodies: Implications for antibody-mediated rejection.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020Review
- Phase I trial of donor-derived modified immune cell infusion in kidney transplantation.The Journal of clinical investigation · 2020Article
- The proportion of CD19Annals of translational medicine · 2019Article
- Tissue talks: immunophenotype of cells infiltrating the graft explains histological findings and the benefits of belatacept at 10 years.Clinical and experimental immunology · 2019Article
- Peripheral blood lymphocyte subsets change after steroid withdrawal in renal allograft recipients: a prospective study.Scientific reports · 2019Article
- Regulatory and Effector B Cells: A New Path Toward Biomarkers and Therapeutic Targets to Improve Transplant Outcomes?Clinics in laboratory medicine · 2019Review
- Effector and regulatory B cells in immune-mediated kidney disease.Nature reviews. Nephrology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCD19+CD24hiCD38hi transitional immature B-lymphocytes have been demonstrated to play an important role in regulating the alloimmune response in transplant recipients. Here, we analyzed the effect of calcineurin inhibition on these peripherally circulating regulatory B-cells (Breg) in renal transplant recipients receiving cyclosporine A (CsA) or tacrolimus.
methodsPBMCs from healthy subjects (HS) (n = 16) and renal transplant recipients (n = 46) were isolated. Flow cytometry was performed for CD19, CD24, CD38 and IL-10 either after isolation or after 72 hours of co-culture in presence of PMA/Ionomycin and TLR9-ligand in presence or absence of increasing concentrations of tacrolimus or CsA.
resultsThe amount of CD19+ B-cells among lymphocytes was ∼9.1% in HS, ∼3.6% in CsA (n = 11, p<0.05) and ∼6.4% in TAC (n = 35, p<0.05) treated patients. Among B-cells, a distinct subset of Breg was found to be 4.7% in HS, 1.4% in tacrolimus treated patients and almost blunted in patients receiving CsA. Similarily, ∼4% of B-cells in HS and even fewer in CsA or tacrolimus treated patients produced IL-10 (0.5% and 1.5%, p<0.05) and this was confirmed both in non-transplanted CsA-treated healthy subjects and in in vitro co-culture experiments. Among 29 patients with <1% of Breg, 9 cases (31%) displayed an allograft rejection in contrast to only one case of rejection (6%) among 17 patients with >1%.
conclusionCalcineurin inhibitors reduce number and IL-10 production of Bregs in the peripheral circulation of both renal transplant recipients and non-transplanted healthy subjects. CNI induced Breg reduction is not restricted to a solid organ transplant setting and is not mediated by co-medication with steroids or MPA. A low proportion of Breg cells is associated with an elevated frequency of allograft rejection events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.